Safety and Efficacy of Insulin Aspart in Type 2 Diabetes

An Open-labelled, Single-arm, Multi-centre, 6-month Study to Investigate the Safety and Efficacy of NovoRapid as Meal Time Insulin in Type 2 Diabetes Patients Treated on a Basal-bolus Regimen With NPH Human Insulin

This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral Protamine Hagedorn (NPH) human insulin.

Inclusion Criteria:

• Type 2 diabetes
• Treated with insulin for at least 12 months and currently on a basal-bolus regimen for at least 12 weeks
• HbA1c below or equal to 11.0%
• BMI (body mass index) below 30 kg/m^2